A5523912
MLN9708 , ≥98% , 1201902-80-8
CAS NO.：1201902-80-8
Empirical Formula: C20H23BCl2N2O9
Molecular Weight: 517.12
MDL number: MFCD18251437
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB103.20 | In Stock |
|
| 10MG | RMB159.20 | In Stock |
|
| 50MG | RMB271.20 | In Stock |
|
| 100MG | RMB435.20 | In Stock |
|
| 500MG | RMB1575.20 | In Stock |
|
| 1G | RMB3119.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | >227°C (dec.) |
| Density | 1.47 |
| storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | DMSO (Slightly), Methanol (Slightly, Heated, Sonicated) |
| pka | 1.92±0.20(Predicted) |
| form | Solid |
| color | White to Off-White |
Description and Uses
Ixazomib citrate is a proteasome inhibitor prodrug for the treatment of multiple myeloma in patients who have received at least one prior therapy in combination with lenalidomide and dexamethasone. The drug was developed by Takeda and reversibly inhibits the protein proteasome subunit β type-5, which is part of the 20S proteasome complex. Ixazomib citrate (XXIV) is hydrolyzed quickly in vivo to give the biologically active compound ixazomib, which presumably is the corresponding boronic acid variant of XXIV.
MLN-9708 is a novel proteasome?inhibitor.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| Safety Statements | 24/25 |
| HS Code | 29329990 |
